Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

Andrew W. Roberts, Ranjana H. Advani, Brad S. Kahl, Daniel Persky, John W. Sweetenham, Dennis A. Carney, Jianning Yang, Todd B. Busman, Sari H. Enschede, Roderick A. Humerickhouse, John F. Seymour

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The oral BCL2 inhibitor navitoclax has moderate single-agent efficacy in chronic lymphocytic leukaemia (CLL) and minor activity in lymphoma in Phase 1 trials. Navitoclax synergizes with rituximab in preclinical models of B-cell lymphoid cancers. We report the safety, pharmacokinetics and clinical activity of this combination. Patients received navitoclax (200-325 mg) daily and four standard weekly doses of rituximab. Twenty-nine patients were enrolled across three dose-escalation cohorts and a safety expansion cohort (250 mg/d navitoclax). The combination was well tolerated. Common toxicities were mild diarrhoea (79%) and nausea (72%). Grade 4 thrombocytopenia occurred in 17% of patients (dose limiting at 325 mg/d). CD19+ counts were severely reduced, while CD3+ cells (∼ 20%) and serum immunoglobulin M levels (∼ 33%) were also reduced during the first year. The maximum tolerated dose for navitoclax in combination was 250 mg/d. Pharmacokinetic analyses revealed no apparent interactions between the drugs. The response rate in patients with follicular lymphoma was 9/12, including five complete responses. All five patients with CLL/small lymphocytic leukaemia achieved partial responses. One of nine patients with aggressive lymphoma responded. The addition of rituximab to navitoclax 250 mg/d is safe; the combination demonstrates higher response rates for low-grade lymphoid cancers than observed for either agent alone in previous Phase 1 trials.

Original languageEnglish (US)
Pages (from-to)669-678
Number of pages10
JournalBritish Journal of Haematology
Volume170
Issue number5
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Pharmacokinetics
Safety
Neoplasms
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Lymphoid Leukemia
Follicular Lymphoma
Maximum Tolerated Dose
Drug Interactions
Nausea
Immunoglobulin M
navitoclax
Rituximab
Diarrhea
B-Lymphocytes
Serum

Keywords

  • B-cell malignancy
  • BCL2
  • Navitoclax
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. / Roberts, Andrew W.; Advani, Ranjana H.; Kahl, Brad S.; Persky, Daniel; Sweetenham, John W.; Carney, Dennis A.; Yang, Jianning; Busman, Todd B.; Enschede, Sari H.; Humerickhouse, Roderick A.; Seymour, John F.

In: British Journal of Haematology, Vol. 170, No. 5, 01.09.2015, p. 669-678.

Research output: Contribution to journalArticle

Roberts, Andrew W. ; Advani, Ranjana H. ; Kahl, Brad S. ; Persky, Daniel ; Sweetenham, John W. ; Carney, Dennis A. ; Yang, Jianning ; Busman, Todd B. ; Enschede, Sari H. ; Humerickhouse, Roderick A. ; Seymour, John F. / Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. In: British Journal of Haematology. 2015 ; Vol. 170, No. 5. pp. 669-678.
@article{fc6880bcf2db42ec908d0490d6dc1560,
title = "Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies",
abstract = "The oral BCL2 inhibitor navitoclax has moderate single-agent efficacy in chronic lymphocytic leukaemia (CLL) and minor activity in lymphoma in Phase 1 trials. Navitoclax synergizes with rituximab in preclinical models of B-cell lymphoid cancers. We report the safety, pharmacokinetics and clinical activity of this combination. Patients received navitoclax (200-325 mg) daily and four standard weekly doses of rituximab. Twenty-nine patients were enrolled across three dose-escalation cohorts and a safety expansion cohort (250 mg/d navitoclax). The combination was well tolerated. Common toxicities were mild diarrhoea (79{\%}) and nausea (72{\%}). Grade 4 thrombocytopenia occurred in 17{\%} of patients (dose limiting at 325 mg/d). CD19+ counts were severely reduced, while CD3+ cells (∼ 20{\%}) and serum immunoglobulin M levels (∼ 33{\%}) were also reduced during the first year. The maximum tolerated dose for navitoclax in combination was 250 mg/d. Pharmacokinetic analyses revealed no apparent interactions between the drugs. The response rate in patients with follicular lymphoma was 9/12, including five complete responses. All five patients with CLL/small lymphocytic leukaemia achieved partial responses. One of nine patients with aggressive lymphoma responded. The addition of rituximab to navitoclax 250 mg/d is safe; the combination demonstrates higher response rates for low-grade lymphoid cancers than observed for either agent alone in previous Phase 1 trials.",
keywords = "B-cell malignancy, BCL2, Navitoclax, Rituximab",
author = "Roberts, {Andrew W.} and Advani, {Ranjana H.} and Kahl, {Brad S.} and Daniel Persky and Sweetenham, {John W.} and Carney, {Dennis A.} and Jianning Yang and Busman, {Todd B.} and Enschede, {Sari H.} and Humerickhouse, {Roderick A.} and Seymour, {John F.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/bjh.13487",
language = "English (US)",
volume = "170",
pages = "669--678",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

AU - Roberts, Andrew W.

AU - Advani, Ranjana H.

AU - Kahl, Brad S.

AU - Persky, Daniel

AU - Sweetenham, John W.

AU - Carney, Dennis A.

AU - Yang, Jianning

AU - Busman, Todd B.

AU - Enschede, Sari H.

AU - Humerickhouse, Roderick A.

AU - Seymour, John F.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - The oral BCL2 inhibitor navitoclax has moderate single-agent efficacy in chronic lymphocytic leukaemia (CLL) and minor activity in lymphoma in Phase 1 trials. Navitoclax synergizes with rituximab in preclinical models of B-cell lymphoid cancers. We report the safety, pharmacokinetics and clinical activity of this combination. Patients received navitoclax (200-325 mg) daily and four standard weekly doses of rituximab. Twenty-nine patients were enrolled across three dose-escalation cohorts and a safety expansion cohort (250 mg/d navitoclax). The combination was well tolerated. Common toxicities were mild diarrhoea (79%) and nausea (72%). Grade 4 thrombocytopenia occurred in 17% of patients (dose limiting at 325 mg/d). CD19+ counts were severely reduced, while CD3+ cells (∼ 20%) and serum immunoglobulin M levels (∼ 33%) were also reduced during the first year. The maximum tolerated dose for navitoclax in combination was 250 mg/d. Pharmacokinetic analyses revealed no apparent interactions between the drugs. The response rate in patients with follicular lymphoma was 9/12, including five complete responses. All five patients with CLL/small lymphocytic leukaemia achieved partial responses. One of nine patients with aggressive lymphoma responded. The addition of rituximab to navitoclax 250 mg/d is safe; the combination demonstrates higher response rates for low-grade lymphoid cancers than observed for either agent alone in previous Phase 1 trials.

AB - The oral BCL2 inhibitor navitoclax has moderate single-agent efficacy in chronic lymphocytic leukaemia (CLL) and minor activity in lymphoma in Phase 1 trials. Navitoclax synergizes with rituximab in preclinical models of B-cell lymphoid cancers. We report the safety, pharmacokinetics and clinical activity of this combination. Patients received navitoclax (200-325 mg) daily and four standard weekly doses of rituximab. Twenty-nine patients were enrolled across three dose-escalation cohorts and a safety expansion cohort (250 mg/d navitoclax). The combination was well tolerated. Common toxicities were mild diarrhoea (79%) and nausea (72%). Grade 4 thrombocytopenia occurred in 17% of patients (dose limiting at 325 mg/d). CD19+ counts were severely reduced, while CD3+ cells (∼ 20%) and serum immunoglobulin M levels (∼ 33%) were also reduced during the first year. The maximum tolerated dose for navitoclax in combination was 250 mg/d. Pharmacokinetic analyses revealed no apparent interactions between the drugs. The response rate in patients with follicular lymphoma was 9/12, including five complete responses. All five patients with CLL/small lymphocytic leukaemia achieved partial responses. One of nine patients with aggressive lymphoma responded. The addition of rituximab to navitoclax 250 mg/d is safe; the combination demonstrates higher response rates for low-grade lymphoid cancers than observed for either agent alone in previous Phase 1 trials.

KW - B-cell malignancy

KW - BCL2

KW - Navitoclax

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84938981686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938981686&partnerID=8YFLogxK

U2 - 10.1111/bjh.13487

DO - 10.1111/bjh.13487

M3 - Article

C2 - 25942994

AN - SCOPUS:84938981686

VL - 170

SP - 669

EP - 678

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -